Vanda Pharmaceuticals Inc
VNDA
View Detailed Chart
6.829USD
-0.201-2.86%
Market hours （ET）Quotes delayed by 15 min
403.58MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-2.86%
5 Days
+3.00%
1 Month
+42.27%
6 Months
+51.42%
Year to Date
+42.57%
1 Year
+42.87%
View Detailed Chart
TradingKey Stock Score of Vanda Pharmaceuticals Inc
Currency: USD Updated: 2025-12-22Key Insights
Vanda Pharmaceuticals Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 16/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.75.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Vanda Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
4
analysts
Buy
Current Rating
11.750
Target Price
+91.37%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Vanda Pharmaceuticals Inc Highlights
StrengthsRisks
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Fairly Valued
The company’s latest PE is -4.91, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 46.45M shares, decreasing 17.70% quarter-over-quarter.
Held by Murray Stahl
Star Investor Murray Stahl holds 25.91K shares of this stock.
Vanda Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Vanda Pharmaceuticals Inc Info
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
Ticker SymbolVNDA
CompanyVanda Pharmaceuticals Inc
CEOPolymeropoulos (Mihael Hristos)
Websitehttps://www.vandapharma.com/
FAQs
What is the current price of Vanda Pharmaceuticals Inc (VNDA)?
The current price of Vanda Pharmaceuticals Inc (VNDA) is 6.829.
What is the symbol of Vanda Pharmaceuticals Inc?
The ticker symbol of Vanda Pharmaceuticals Inc is VNDA.
What is the 52-week high of Vanda Pharmaceuticals Inc?
The 52-week high of Vanda Pharmaceuticals Inc is 7.050.
What is the 52-week low of Vanda Pharmaceuticals Inc?
The 52-week low of Vanda Pharmaceuticals Inc is 3.809.
What is the market capitalization of Vanda Pharmaceuticals Inc?
The market capitalization of Vanda Pharmaceuticals Inc is 403.58M.
What is the net income of Vanda Pharmaceuticals Inc?
The net income of Vanda Pharmaceuticals Inc is -18.90M.
Is Vanda Pharmaceuticals Inc (VNDA) currently rated as Buy, Hold, or Sell?
According to analysts, Vanda Pharmaceuticals Inc (VNDA) has an overall rating of Buy, with a price target of 11.750.
What is the Earnings Per Share (EPS TTM) of Vanda Pharmaceuticals Inc (VNDA)?
The Earnings Per Share (EPS TTM) of Vanda Pharmaceuticals Inc (VNDA) is -1.431.
Related Instruments
-0.35%
-0.77%
+0.63%
+0.67%
+1.56%
-0.15%
+0.12%
+6.53%
+1.58%
-0.89%
+0.56%
-0.03%
-0.76%
+0.82%
+0.38%
+1.25%
+0.99%
0.00%
-0.28%
-2.24%Popular Symbols
